XHEL
BIOBV
Market cap40mUSD
Oct 09, Last price
2.32EUR
1D
-0.43%
1Q
-13.43%
Jan 2017
-61.65%
Name
Biohit Oyj
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.
Key people
Lea Paloheimo
Independent Chairman of the Board · since 2022
Graham Johnson
Managing Director of Biohit Healthcare Ltd. · since 2011
Ilari Patrakka
Sales and Marketing Director, Member of the Management Team · since 2016
Annika Astola
Quality Director, Member of the Management Team · since 2014
Suvi Elomaa
Production Manager, Member of the Management Board · since 2021
Jussi Hahtela
Chief Executive Officer, Member of the Management Board · since 2022
Panu Hendolin
Head - Research & Development, Member of the Management Board · since 2022
Daniela Soderstrom
Quality and Regulatory Affairs Director, Member of the Management Team · since 2016
Jussi Sorvo
Chief Financial Officer, Member of the Management Board · since 2022
Franco Aiolfi
Director, Managing Director of Biohit Healthcare S.r.l.
Liu Feng
Director · since 2018
Matti Harkonen
Director · since 2017
Osmo Suovaniemi
Chairman of the Board, Deputy Chief Executive Officer · since 2021
Kalle Harkonen
Independent Director · since 2022
Eero Lehti
Independent Director · since 2009
Headquarters & legal address
LAIPPATIE 1
00880 HELSINKI
HELSINKI FI-00880
FI
00880 HELSINKI
HELSINKI FI-00880
FI
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||